Alamar Biosciences, INC

Alamar Biosciences announced the passing of board member Ian Ratcliffe and subsequent adjustments to its board size and committee appointments.

Sands Capital Life Sciences Pulse Fund II, L.P. reports a 6.1% stake in Alamar Biosciences, Inc. following the passing of board member Ian Ratcliffe.

Yuling Luo has reported beneficial ownership of 6.4% of Alamar Biosciences' common stock as of June 30, 2026, including exercisable options and shares held by spouse.

Several Qiming entities have entered into a joint filing agreement to collectively report their beneficial ownership of Alamar Biosciences, Inc. common stock.

Sherpa Healthcare Fund II, L.P. and Sherpa Healthcare Co-Investment Fund, L.P., along with Daqing Cai, have reported beneficial ownership of 7.2% of Alamar Biosciences, Inc. common stock.